Company Information

Company Santen Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
Publicly Listed
Global Compact Status:
Participant Since
23 October 2017
Letter of Commitment
Next Communication on Progress (COP) due on:
31 July 2024

Financial Information

Communication On Progress

Published On Title Level/Status
18-Dec-2023 2023 Communication on Progress Submitted
20-Oct-2022 Communication on Progress Active
20-Oct-2021 Communication on Progress Active
21-Oct-2020 Communication on Progress Active
22-Oct-2019 Communication on Progress Active
22-Oct-2018 Santen Annual Report 2018 Active

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.